[Originating GP surgery’s letterhead/logo/address details]

Mrs/Miss/Ms [add patient’s name]

[Add address line 1]

[Add address line 2]

[Add address line 3]

[Add address line 4]

[add date]

Dear Mrs/Miss/Ms [add patient’s name],

**Reminder: the name of your oral contraceptive has changed from:**

**Marvelon®** (30 mcg ethinylestradiol + 150 mcg desogestrel)

**To:**

**Cimizt®** (30 mcg ethinylestradiol + 150 mcg desogestrel)

Cimizt® contains the **same active ingredients in the same amounts** as Marvelon®,and is therefore considered to **work in the same way.1–4**

Please continue to take Marvelon®until you run out of tablets. As Cimizt® is the same strength as Marvelon®, after your normal ‘pill-free’ interval, simply start taking Cimizt® in the same way you took Marvelon®.1,2

Your Cimizt® pack will contain a Patient Information Leaflet, which will answer many of the questions you may have about your new brand of pill. You can also find out about Cimizt® at: [www.morningsidecontraceptives.com](http://www.morningsidecontraceptives.com). Simply go the website, click on ‘*I have been prescribed a Morningside Contraceptive’* then select ‘*view more*’ under Cimizt®.

Changing to Cimizt® is as simple as getting used to the new packaging – you’ll take the same number of tablets each month, and request repeat prescriptions in the same way as when you took Marvelon®.1,2 When taken correctly, Cimizt® is just as effective at preventing pregnancy as Marvelon®.3,4 However, if you wish to discuss this change then please arrange to speak with one of our GPs or our Family Planning Nurse.

Yours sincerely,

Dr [add name]

Dr [add name] and Partners

**Cimizt®** is a registered trademark of Morningside Healthcare Ltd

**Marvelon®** is a registered trademark of Organon Pharma (UK) Ltd

1. Organon Pharma (UK) Ltd. Marvelon Tablets. Summary of Product Characteristics. April 2022. Available at: https://www.medicines.org.uk/emc/product/1359 (accessed August 2022);
2. Morningside Healthcare Ltd. Cimizt 150 microgram/30 microgram Tablets. Summary of Product Characteristics. August 2021. Available at: https://www.medicines.org.uk/emc/product/9568 (accessed August 2022);
3. MHRA. UK PAR Cimizt 150 microgram/30 microgram tablets. Available at: https://mhraproductsproduction.blob.core.windows.net/docs/4a1ca9185731e16b811c8e44107621fcb279801e
(accessed August 2022);
4. Netherlands Medicines Evaluation Board. Public Assessment Report Desogestrel/Ethinylestradiol Famy 150/20 and 150/30 microgram tablets. August 2012. Available at: https://www.geneesmiddeleninformatiebank.nl/Pars/h108164.pdf
(accessed August 2022).